Search Results - M. Dimopoulos

  • Showing 1 - 9 results of 9
Refine Results
  1. 1

    Interventional Oncology for Colorectal Liver Metastases: From Local Cure to Salvage Therapy by Dimitrios Xenos, Vlasios S. Sotirchos, Platon M. Dimopoulos, Constantinos T. Sofocleous

    Published in Biomedicines (2025-09-01)
    Get full text
    Article


  2. 2

    A novel microrna signature with clinical significance in multiple myeloma by A. Papanota, P. Artemaki, P. Karousi, C. Liacos, M. Gavriatopoulou, E. Kastritis, C. Kontos, M. Dimopoulos, A. Scorilas, E. Terpos

    Published in Hematology, Transfusion and Cell Therapy (2020-10-01)
    Get full text
    Article


  3. 3

    P901: POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN LENALIDOMIDE–PRETREATED MULTIPLE MYELOMA: A SUBANALYSIS OF OPTIMISMM BY FRAILTY by A. Oriol, M. Dimopoulos, F. Schjesvold, M. Beksac, M. Yagci, A. Larocca, S. Guo, Y. Mu, K. Hong, S. Dhanasiri, P. Richardson, K. Weisel

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  4. 4

    Peripheral blood immune profiling of multiple myeloma patients at diagnosis: correlations with circulating plasma cells by K. Papadimitriou, I. Ntanasis-Stathopoulos, N. Tsakirakis, M. Gavriatopoulou, I. Kostopoulos, E. Kastritis, N. Orologas-Stavrou, M. Dimopoulos, O. Tsitsilonis, E. Terpos

    Published in Hematology, Transfusion and Cell Therapy (2020-10-01)
    Get full text
    Article


  5. 5

    Isatuximab plus carfilzomib and dexamethasone vs. carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (ikema): interim analysis of a phase 3, randomized, open-lab... by M. Turgut, P. Moreau, M. Dimopoulos, J. Mikhael, K. Yong, M. Capra, T. Facon, R. Hajek, I. Spicka, M. Risse, G. Asset, S. Macé, T. Martin

    Published in Hematology, Transfusion and Cell Therapy (2020-10-01)
    Get full text
    Article


  6. 6

    P926: DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: RESULTS FROM THE PHASE 2 GMMG-DA... by L. Leypoldt, M. Gavriatopoulou, B. Besemer, H. Salwender, M.-S. Raab, A. Nogai, C. Khandanpour, V. Runde, M. Zago, P. Martus, H. Goldschmidt, C. Bokemeyer, M. Dimopoulos, K. Weisel

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  7. 7

    P1159: A MULTICENTER, INTERNATIONAL COLLABORATIVE STUDY EVALUATING FRONTLINE THERAPY WITH BENDAMUSTINE RITUXIMAB FOR WALDENSTRÖM MACROGLOBULINEMIA by S. Zanwar, J. Abeykoon, J. Castillo, E. Durot, E. Kastritis, E. Uppal, P. Morel, R. Tawfiq, L. Montes, J. Paludo, S. Sarosiek, S. Kumar, O. Ogunbiyi, P. Cornillet-Lefebvre, R. Kyle, A. Delmer, M. Gertz, M. Dimopoulos, S. Ansell, S. Treon, S. D’Sa, P. Kapoor

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  8. 8

    P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN? by R Popat, A Badros, S Kumar, P Rodriguez-Otero, A Cohen, S Manier, P Voorhees, F Gay, R Rifkin, T Martin, A Chari, K Weisel, A Farooq, B Jeng, W Chng, H Lee, J Berdeja, V Jadhav, A Tosolini, L Eliason, A Palumbo, M Dimopoulos, S Lonial, S Trudel, P Richardson, E Terpos

    Published in HemaSphere (2022-04-01)
    Get full text
    Article


  9. 9

    P1161: ASPEN: LONG-TERM FOLLOW-UP RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR) IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM) by M. Dimopoulos, S. Opat, S. D’Sa, W. Jurczak, H.-P. Lee, G. Cull, R. G. Owen, P. Marlton, B. E. Wahlin, R. Garcia-Sanz, H. McCarthy, S. Mulligan, A. Tedeschi, J. J. Castillo, J. Czyz, C. Fernandez De Larrea Rodriguez, D. Belada, E. Libby, J. Matous, M. Motta, T. Siddiqi, M. Tani, M. Trneny, M. Minnema, C. Buske, V. Leblond, S. P. Treon, J. Trotman, W. Y. Chan, J. Schneider, H. Allewelt, A. Cohen, J. Huang, C. S. Tam

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


Search Tools: